These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 21986846)

  • 1. How to manage thrombosis in myeloproliferative neoplasms.
    Barbui T
    Curr Opin Oncol; 2011 Nov; 23(6):654-8. PubMed ID: 21986846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Detection and clinical significance of JAK2 mutation in 412 patients with chronic myeloproliferative neoplasms].
    Chao HY; Fan Z; Zhang R; Shen YM; Chen W; Fei HR; Zhu ZL; Feng YF; Chen ZX; Xue YQ
    Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):510-4. PubMed ID: 19950698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of myeloproliferative neoplasms other than chronic leukemia].
    Ohyashiki JH
    Nihon Rinsho; 2009 Oct; 67(10):1964-8. PubMed ID: 19860198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
    Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
    Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloproliferative neoplasms and thrombosis.
    Barbui T; Finazzi G; Falanga A
    Blood; 2013 Sep; 122(13):2176-84. PubMed ID: 23823316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombosis in myeloproliferative neoplasms.
    Falanga A; Marchetti M
    Semin Thromb Hemost; 2014 Apr; 40(3):348-58. PubMed ID: 24610470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.
    Pikman Y; Levine RL
    Curr Opin Oncol; 2007 Nov; 19(6):628-34. PubMed ID: 17906464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
    De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T;
    Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relation of platelet abnormalities to thrombosis and hemorrhage in chronic myeloproliferative disorders.
    Wehmeier A; Südhoff T; Meierkord F
    Semin Thromb Hemost; 1997; 23(4):391-402. PubMed ID: 9263357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention and Management of Thrombosis in BCR/ABL-Negative Myeloproliferative Neoplasms.
    Falanga A; Marchetti M; Schieppati F
    Hamostaseologie; 2021 Feb; 41(1):48-57. PubMed ID: 33588455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombocytosis and Thrombosis: Is There Really a Correlation?
    Galvez C; Stein BL
    Curr Hematol Malig Rep; 2020 Aug; 15(4):261-267. PubMed ID: 32399765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythromelalgia--a thrombotic complication in chronic myeloproliferative disorders.
    Tarach JS; Nowicka-Tarach BM; Matuszek B; Nowakowski A
    Med Sci Monit; 2000; 6(1):204-8. PubMed ID: 11208311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk.
    Barbui T; Finazzi G
    Semin Thromb Hemost; 2007 Jun; 33(4):321-9. PubMed ID: 17525889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How I Manage Thrombotic/Thromboembolic Complications in Myeloproliferative Neoplasms.
    Koschmieder S
    Hamostaseologie; 2020 Feb; 40(1):47-53. PubMed ID: 32050290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monocyte IL-2Ralpha expression is associated with thrombosis and the JAK2V617F mutation in myeloproliferative neoplasms.
    Goette NP; Lev PR; Heller PG; Kornblihtt LI; Korin L; Molinas FC; Marta RF
    Cytokine; 2010 Jul; 51(1):67-72. PubMed ID: 20483636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High Level of Circulating Microparticles in Patients with BCR/ABL Negative Myeloproliferative Neoplasm - a Pilot Study.
    Aswad MH; Kissová J; Rihova L; Zavrelova J; Ovesná P; Penka M
    Klin Onkol; 2019; 32(2):109-116. PubMed ID: 30995850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How to manage children and young adults with myeloproliferative neoplasms.
    Barbui T
    Leukemia; 2012 Jul; 26(7):1452-7. PubMed ID: 22252311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis.
    De Stefano V; Teofili L; Leone G; Michiels JJ
    Semin Thromb Hemost; 1997; 23(5):411-8. PubMed ID: 9387199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leukocytosis and risk stratification assessment in essential thrombocythemia.
    Carobbio A; Antonioli E; Guglielmelli P; Vannucchi AM; Delaini F; Guerini V; Finazzi G; Rambaldi A; Barbui T
    J Clin Oncol; 2008 Jun; 26(16):2732-6. PubMed ID: 18443353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High rate of abnormal blood values and vascular complications before diagnosis of myeloproliferative neoplasms.
    Enblom A; Lindskog E; Hasselbalch H; Hersby D; Bak M; Tetu J; Girodon F; Andréasson B
    Eur J Intern Med; 2015 Jun; 26(5):344-7. PubMed ID: 25863408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.